Drug profile · INN
omalizumab-igec
OMLYCLO
omalizumab-igec (OMLYCLO) is a ig epsilon chain c region inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — omalizumab-igec
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
omalizumab-igec (OMLYCLO) is a ig epsilon chain c region inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Ig epsilon chain C region inhibitor
Primary target: Immunoglobulin heavy constant epsilon
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is omalizumab-igec?
omalizumab-igec (OMLYCLO) is a ig epsilon chain c region inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for omalizumab-igec?
OMLYCLO is a marketed brand name for omalizumab-igec. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omalizumab-igec?
omalizumab-igec has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.